Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 298

1.

CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Uckun FM, Qazi S, Ma H, Reaman GH, Mitchell LG.

Integr Biol (Camb). 2015 Feb;7(2):237-49. doi: 10.1039/c4ib00221k.

PMID:
25567759
2.

Remaining challenges in childhood cancer and newer targeted therapeutics.

Smith MA, Reaman GH.

Pediatr Clin North Am. 2015 Feb;62(1):301-12. doi: 10.1016/j.pcl.2014.09.018. Epub 2014 Oct 18. Review.

PMID:
25435124
3.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

PMID:
25399948
4.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27.

PMID:
25348002
5.

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL.

Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.

6.

International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.

Sadak KT, Fultz K, Mendizabal A, Reaman G, Garcia-Gonzalez P, Levine PH.

Pediatr Blood Cancer. 2014 Oct;61(10):1774-8. doi: 10.1002/pbc.25120. Epub 2014 Jun 29.

PMID:
24976310
7.

The Children's Oncology Group Childhood Cancer Research Network (CCRN): case catchment in the United States.

Musselman JR, Spector LG, Krailo MD, Reaman GH, Linabery AM, Poynter JN, Stork SK, Adamson PC, Ross JA.

Cancer. 2014 Oct 1;120(19):3007-15. doi: 10.1002/cncr.28813. Epub 2014 May 29.

8.

Declining childhood and adolescent cancer mortality.

Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL.

Cancer. 2014 Aug 15;120(16):2497-506. doi: 10.1002/cncr.28748. Epub 2014 May 22.

PMID:
24853691
9.

DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.

Shah ED, Fisch BM, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP.

Cancer Chemother Pharmacol. 2014 May;73(5):1089-93. doi: 10.1007/s00280-014-2433-9. Epub 2014 Mar 25.

PMID:
24663501
10.

Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA).

Al-Mulla NA, Chandra P, Khattab M, Madanat F, Vossough P, Torfa E, Al-Lamki Z, Zain G, Muwakkit S, Mahmoud S, Al-Jassmi A, Tuncer M, Al-Mukharraq H, Barsaoui S, Arceci RJ, Howard SC, Kulozik AE, Ravindranath Y, Reaman GH, Farranoush M, AlNasser AA.

Pediatr Blood Cancer. 2014 Aug;61(8):1403-10. doi: 10.1002/pbc.25031. Epub 2014 Mar 20.

PMID:
24648275
11.

Pediatric oncology drug shortages: a multifaceted problem.

Murphy D, Reaman G, Jensen CV.

Pediatrics. 2014 Mar;133(3):e728-9. doi: 10.1542/peds.2013-4018. Epub 2014 Feb 2. No abstract available.

12.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.

Blood. 2013 Jul 25;122(4):507-14. doi: 10.1182/blood-2013-01-480822. Epub 2013 Jun 5.

13.

Patient-perceived facilitators in the transition of care for young adult survivors of childhood cancer.

Sadak KT, Dinofia A, Reaman G.

Pediatr Blood Cancer. 2013 Aug;60(8):1365-8. doi: 10.1002/pbc.24494. Epub 2013 Feb 25. Review.

PMID:
23441065
14.

Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries.

Pritchard-Jones K, Pieters R, Reaman GH, Hjorth L, Downie P, Calaminus G, Naafs-Wilstra MC, Steliarova-Foucher E.

Lancet Oncol. 2013 Mar;14(3):e95-e103. doi: 10.1016/S1470-2045(13)70010-X. Epub 2013 Feb 20.

PMID:
23434338
15.

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA.

Blood. 2013 Apr 4;121(14):2689-703. doi: 10.1182/blood-2012-04-425033. Epub 2013 Feb 7.

16.

The impact of the written request process on drug development in childhood cancer.

Snyder KM, Reaman G, Avant D, Pazdur R.

Pediatr Blood Cancer. 2013 Apr;60(4):531-7. doi: 10.1002/pbc.24346. Epub 2013 Jan 17.

PMID:
23335552
17.

American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.

McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, Hudson MM.

J Clin Oncol. 2013 Feb 10;31(5):631-40. doi: 10.1200/JCO.2012.46.6854. Epub 2013 Jan 7. No abstract available.

18.

Recommendations for the return of research results to study participants and guardians: a report from the Children's Oncology Group.

Fernandez CV, Ruccione K, Wells RJ, Long JB, Pelletier W, Hooke MC, Pentz RD, Noll RB, Baker JN, O'Leary M, Reaman G, Adamson PC, Joffe S; COG Return of Results Task Force.

J Clin Oncol. 2012 Dec 20;30(36):4573-9. doi: 10.1200/JCO.2012.45.2086. Epub 2012 Oct 29.

19.

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.

Yang JJ, Cheng C, Devidas M, Cao X, Campana D, Yang W, Fan Y, Neale G, Cox N, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Bowman WP, Camitta B, Reaman GH, Carroll WL, Willman CL, Hunger SP, Evans WE, Pui CH, Loh M, Relling MV.

Blood. 2012 Nov 15;120(20):4197-204. doi: 10.1182/blood-2012-07-440107. Epub 2012 Sep 24.

20.

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG.

Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk